Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Alnylam Pharmaceuticals Inc(ALNY)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ALNY
09/25/2026: ALNY (1-star) is currently NOT-A-BUY. Pass it for now.
Alnylam Pharmaceuticals is a pioneer in RNA interference (RNAi) therapy, holding a leading position in the development of gene-silencing medicines for rare diseases. The company's primary strength lies in its validated drug delivery platform and a growing portfolio of FDA-approved products like ONPATTRO and AMVUTTRA. The central investment story centers on the company’s potential to expand from rare orphan diseases into massive cardiometabolic markets. Key risks include intense competition from gene-editing modalities, high R&D-driven operating costs, and binary clinical trial outcomes. The stock is best suited for growth-oriented investors with a high risk tolerance, and observers should monitor upcoming clinical trial results and label expansion successes.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company is in an active growth phase with a pipeline targeting large-scale health conditions. |
| Momentum investor | Mixed fit | Stock price often reacts sharply to clinical and regulatory news cycles. |
| Value investor | Weak fit | Current valuation is based on future growth potential rather than current earnings multiples. |
| Dividend investor | Weak fit | The company does not pay dividends, focusing entirely on growth. |
| Low-risk investor | Weak fit | High volatility associated with biotech clinical outcomes makes this unsuitable for risk-averse investors. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | The stock is sensitive to binary clinical trial events. |
| Valuation risk | Medium / high | Premium valuations are tied to long-term pipeline success. |
| Competition risk (Genetic medicine) | Medium | Competition from gene editing and other RNA modalities is intensifying. |
| Business quality | Strong | Alnylam owns a foundational and well-validated technology platform. |
| Dividend income | Low / none | No income is returned to shareholders. |
| Execution risk | Medium | Successfully expanding into larger markets requires complex commercial scaling. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Choppy
The stock has experienced frequent reversals and pronounced short-term price swings.
Analysis of Past Performance
Type Stock | Historic Profit 68.96% | Avg. Invested days 38 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  2.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/25/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 33.40B USD | Price to earnings Ratio 42.88 | 1Y Target Price 371.35 |
Price to earnings Ratio 42.88 | 1Y Target Price 371.35 | ||
Volume (30-day avg) 1.6M shares | Beta 0.3 | 52 Weeks Range 197.81 - 495.55 | Updated Date 09/25/2026 |
52 Weeks Range 197.81 - 495.55 | Updated Date 09/25/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 5.82 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Commercialized RNAi Drugs | Global sales of ONPATTRO, AMVUTTRA, GIVLAARI, and OXLUMO. | The company generates revenue by selling specialized, high-cost medicines for rare diseases. |
| Strategic Collaborations | Milestone payments and royalties from pharma partnerships. | The company earns extra cash by letting other big drug companies use its technology. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE 42.88 | Forward PE 19.68 | Enterprise Value 30.94B | Price to Sales(TTM) 6.95 |
Enterprise Value 30.94B | Price to Sales(TTM) 6.95 | ||
Enterprise Value to Revenue 6.58 | Enterprise Value to EBITDA 28.62 | Shares Outstanding 133.81M | Shares Floating 133.24M |
Shares Outstanding 133.81M | Shares Floating 133.24M | ||
Percent Insiders 0.18 | Percent Institutions 101.67 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Alnylam Pharmaceuticals Inc
Exchange NASDAQ | Headquarters Cambridge, MA, United States | ||
IPO Launch date 2004-05-28 | CEO & Director Dr. Yvonne L. Greenstreet M.B.A., M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2500 | Website https://www.alnylam.com |
Full time employees 2500 | Website https://www.alnylam.com | ||
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1. It also develops a range of products in Phase 3 trial, such as Nucresiran for ATTR amyloidosis; Zilebesiran for hypertension; Cemdisiran for myasthenia gravis, paroxysmal nocturnal hemoglobinuria, and geographic atrophy; and Elebsiran for hepatitis D virus infections. In addition, the company is developing various products in Phase 2 trial, including Rapirosiran for metabolic dysfunction-associated steatohepatitis; ALN-ANG3 for diabetic kidney disease; ALN-4324 for type 2 diabetes mellitus; Mivelsiran for cerebral amyloid angiopathy, as well as in Phase 1 trial for Alzheimer's disease; and ALN-6400 for bleeding disorders. Further, it develops a range of products in Phase 1 trial, such as ALN-2232 for obesity and weight management; ALN-PNP for non-alcoholic fatty liver disease; ALN-APOC3 for dyslipidemia; ALN-CIDEB for metabolic dysfunction-associated steatohepatitis; ALN-HTT02 for Huntington's disease; ALN-5288 for Alzheimer's disease; ALN-SOD for SOD1 amyotrophic lateral sclerosis; ALN-SNCA for Parkinson's disease; AG-236 for polycythemia vera; ALN-CFB for paroxysmal nocturnal hemoglobinuria; ALN-BCAT for hepatocellular carcinoma; and ALN-4285, ALN-4915, and ALN-F1202 for healthy volunteers. The company has collaborations with Regeneron Pharmaceuticals, Inc.; Roche Holding AG; Sanofi S.A.; Novartis AG; PeptiDream, Inc; Dicerna Pharmaceuticals, Inc.; and Ionis Pharmaceuticals, Inc. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.